Biosensor for Diagnosing Factor V Leiden, A Single Amino Acid Mutated Abnormality of Factor V

Author(s):  
Yongjie Ren ◽  
Samin Rezania ◽  
Kyung A. Kang
Blood ◽  
2005 ◽  
Vol 106 (11) ◽  
pp. 724-724
Author(s):  
Bin Zhang ◽  
Beth McGee ◽  
William C. Nichols ◽  
Hugo Guglielmone ◽  
Katherine Downes ◽  
...  

Abstract Factor V (FV) and factor VIII (FVIII) are two large plasma glycoproteins that function as essential cofactors for the proteolytic activation of prothrombin and factor X, respectively. Efficient biosynthesis of FV and FVIII requires LMAN1 and MCFD2, two proteins localized to the early secretory pathway of the cell. LMAN1 is a 53-kD homo-hexameric transmembrane protein with homology to leguminous mannose-binding lectins. MCFD2 is an EF-hand domain protein that co-localizes with LMAN1 to the ER-Golgi intermediate compartment (ERGIC). MCFD2 interacts with LMAN1 to form a stable, calcium-dependent protein complex that functions as a cargo receptor, ferrying FV and FVIII from the endoplasmic reticulum to the Golgi. Mutations in LMAN1 or MCFD2 cause combined deficiency of factors V and VIII, an autosomal recessive disorder associated with plasma levels of FV and FVIII in the range of 5% to 30% of normal. However, three families were found to have no LMAN1 or MCFD2 mutations, with 2 of these families showing genetic evidence against linkage to either gene, raising the possibility of additional locus heterogeneity and the involvement of a third F5F8D gene. We now report the analysis of 10 previously reported and 9 new F5F8D families. We identified 3 MCFD2 mutations accounting for 6 F5F8D families, and 8 LMAN1 mutations accounting for 8 additional families, including the first-reported single amino acid substitution, replacement of cysteine at amino acid position 475 with arginine (C475R). Cysteine 475 was previously reported to be important in forming an intermolecular disulfide bond required for LMAN1 oligomerization. However, C475R LMAN1 was undetected by Western blot analysis in lymphoblasts derived from a patient hemizygous for this mutation, with only a trace of protein detectable by immunoprecipitation. Thus, the C475R mutation appears to result in an unstable LMAN1 protein that is rapidly degraded. Failure of proteasome inhibitors to increase the intracellular accumulation of this protein suggests an alternative degradation pathway. Finally, two LMAN1 alleles for which no mutations were identified were nonetheless shown to result in no detectable LMAN1 mRNA, indicating a cis-defect in transcription or mRNA stability. Taken together with our previous reports, we have now identified LMAN1 or MCFD2 mutations as the causes of F5F8D in 70 of 75 families. Two of the remaining 5 families are consistent with linkage to the LMAN1 or MCFD2 loci, suggesting mutations in the regulatory region of the genes that were missed by direct sequencing. Reanalysis of the remaining 3 families suggests an initial misdiagnosis, with one reclassified as isolated, mild FV deficiency, and two others as von Willebrand disease. These results suggest that mutations in LMAN1 and MCFD2 account for all cases of F5F8D, with no evidence for a 3rd F5F8D gene.


2005 ◽  
Vol 128 (2) ◽  
pp. 248-252 ◽  
Author(s):  
Bettina Kemkes-Matthes ◽  
Karl J. Matthes ◽  
Masayoshi Souri ◽  
Shiori Koseki-Kuno ◽  
Akitada Ichinose

Blood ◽  
2013 ◽  
Vol 122 (21) ◽  
pp. 458-458
Author(s):  
John A. Heit ◽  
Mariza de Andrade ◽  
Sebastian M Armasu ◽  
Iftikhar J Kullo ◽  
Jyotishman Pathak ◽  
...  

Background The incidence of VTE in African-Americans (AAs) is similar to or higher than in Americans of European ancestry. However, the carrier frequencies of inherited thrombophilias common in whites (i.e., Factor V Leiden, Prothrombin G20210A) are very low in AAs, suggesting that other inherited thrombophilias may be associated with VTE in AAs. Objective To identify potentially novel non-hypothesis-driven single nucleotide polymorphisms (SNPs) associated with VTE in AAs. Methods We used the resources of the eMERGE Network to perform a GWAS of VTE in AAs. The eMERGE Network (funded by NHGRI) is comprised of nine sites each with DNA biobanks linked to electronic health records (EHRs). Approximately 39,206 unique DNA samples have been genotyped using either Affymetrix or Illumina genome-wide SNP arrays. Led by the Coordinating Center and eMERGE genomics workgroup, an imputation pipeline was developed for merging genomic data across the different SNP arrays used by the eMERGE sites, to maximize sample size and the power to detect associations. The imputation was performed using the 1000 Genomes Cosmopolitan reference panel which includes 1092 individuals and over 36 million SNPs. From our previously-identified cohort of Olmsted County, MN residents with incident or recurrent VTE, 1996-2005, we derived and validated an EHR-driven phenotype extraction algorithm that leveraged structured data based on ICD-9-CM codes and unstructured data from clinical notes via natural language processing to identify VTE cases and controls with 100% and 94% positive and negative predictive values, respectively. We tested for an association between each SNP and VTE among AAs using unconditional logistic regression, adjusting for age, sex and eMERGE site. Results Among 294 AA VTE cases and 3,661 AA controls (total n=3,955; females, n=2,512), the Factor V Leiden (F5 rs6025) was not analyzed due to a very low minor allele frequency (MAF=0.0036). The prothrombin G20210A (F2 rs1799963) and ABO blood type O (ABO rs8176719) SNPs were not genotyped in any of the arrays and could not be imputed. Among SNPs with an imputation score >0.8, the most significant SNPs associated with VTE were ITPR3 (inositol 1,4,5-triphosphate receptor type 3) rs2229637 (OR=1.65; p=3.61E-07; MAF=0.19) and CLEC7A (C-type lectin domain family 7, member A) rs59819090 (OR=2.16; p=1.06E-06; MAF=0.056). ITPR3 SNPs have been associated with coronary artery aneurysm in Kawasaki disease, type 1 diabetes mellitus and other autoimmune disorders. CLEC7A rs59819090 encodes for a serine82 to leucine nonsynonymous amino acid change in dectin-1. Dectin-1 is a transmembrane innate immune pattern recognition receptor on myeloid cells that upon binding it’s agonist, β-glucans, stimulates cytokine production and the respiratory burst, a prerequisite for formation of neutrophil extracelluar traps (NETs). NETs have been associated with VTE (van Montfoort, et al. Ateriosclero Thromb Vasc Biol 2013;33:147-51). Dectin-1 serine82 is not evolutionarily conserved and the serine82 to leucine amino acid change is predicted to be tolerated, with a moderate effect on protein function. Conclusions ITPR3 rs2229637 and CLAC7A rs59819090 may be associated with VTE in African-Americans. These observations require replication and functional studies toward understanding how they may lie on the causal pathway to VTE. Disclosures: No relevant conflicts of interest to declare.


2020 ◽  
Vol 12 (1) ◽  
pp. 10-14 ◽  
Author(s):  
Latheef Kasala ◽  
Rajasekhar Durgaprasad ◽  
Vanajakshamma Velam

Introduction: Acute pulmonary thromboembolism (PTE) presents with wide spectrum and has variable prognosis. Factor V Leiden (FVL) is the most common inherited thrombophilia, with a prevalence of 3%-7% in the general US population, approximately 5% in Whites, 2.2% in Hispanics and 1.2% in Blacks. PTE most commonly originates from venous thrombosis. The occurrence of venous thromboembolism is a culmination of environmental and genetic risk factors. The current study was sought to identify the mutations in exon-10 of FV gene in patients with PTE.<br /> Methods: Sixty cases diagnosed with PTE and 50 healthy controls were enrolled in the present study. Mutation studies in exon-10 of Factor V gene included PCR-DNA sequencing method.<br /> Results: Of 60 patients, we found two novel transition type point mutations: c.1538 G>A and c.1601 G>A in exon-10 of Factor V which is responsible for the cleavage site for aPC. These point mutations resulted in single amino acid change in protein sequence at p.Arg513Lys and p.Arg534Gln respectively. These mutations prevent efficient inactivation of Factor V and Factor V remains active which facilitates over production of thrombin leading to generation of excess fibrin and excess coagulation which results in deep vein thrombosis and PTE.<br /> Conclusion: We report two novel point mutations (c.1538 G>A and c.1601 G>A) in exon-10 of Factor V gene in Indian patients with PTE.


2008 ◽  
Vol 41 (7) ◽  
pp. 26-27
Author(s):  
JANE SALODOF MACNEIL
Keyword(s):  

VASA ◽  
2015 ◽  
Vol 44 (4) ◽  
pp. 313-323 ◽  
Author(s):  
Lea Weingarz ◽  
Marc Schindewolf ◽  
Jan Schwonberg ◽  
Carola Hecking ◽  
Zsuzsanna Wolf ◽  
...  

Abstract. Background: Whether screening for thrombophilia is useful for patients after a first episode of venous thromboembolism (VTE) is a controversial issue. However, the impact of thrombophilia on the risk of recurrence may vary depending on the patient’s age at the time of the first VTE. Patients and methods: Of 1221 VTE patients (42 % males) registered in the MAISTHRO (MAin-ISar-THROmbosis) registry, 261 experienced VTE recurrence during a 5-year follow-up after the discontinuation of anticoagulant therapy. Results: Thrombophilia was more common among patients with VTE recurrence than those without (58.6 % vs. 50.3 %; p = 0.017). Stratifying patients by the age at the time of their initial VTE, Cox proportional hazards analyses adjusted for age, sex and the presence or absence of established risk factors revealed a heterozygous prothrombin (PT) G20210A mutation (hazard ratio (HR) 2.65; 95 %-confidence interval (CI) 1.71 - 4.12; p < 0.001), homozygosity/double heterozygosity for the factor V Leiden and/or PT mutation (HR 2.35; 95 %-CI 1.09 - 5.07, p = 0.030), and an antithrombin deficiency (HR 2.12; 95 %-CI 1.12 - 4.10; p = 0.021) to predict recurrent VTE in patients aged 40 years or older, whereas lupus anticoagulants (HR 3.05; 95%-CI 1.40 - 6.66; p = 0.005) increased the risk of recurrence in younger patients. Subgroup analyses revealed an increased risk of recurrence for a heterozygous factor V Leiden mutation only in young females without hormonal treatment whereas the predictive value of a heterozygous PT mutation was restricted to males over the age of 40 years. Conclusions: Our data do not support a preference of younger patients for thrombophilia testing after a first venous thromboembolic event.


1999 ◽  
Vol 81 (04) ◽  
pp. 661-663 ◽  
Author(s):  
Joseph Vaughan ◽  
Cariosa Power ◽  
Catherine Nolan ◽  
Don McCarthy ◽  
Ivan Shirley

Sign in / Sign up

Export Citation Format

Share Document